Skip to main content

Table 4 Response rates of salvage chemotherapy for recurrent or refractory clear cell carcinoma

From: Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment?

regimen author year response/ number of patients, response rate
Megestrol acetate Walailak [45] 2001 2/10, 20%
Cyclopshosphamide+cisplatin Takano [46] 2008 1/9, 11%
Irinotecan+Platinum Sugiyama [29] 1998 1/3, 33%
Takano [46] 2008 2/15, 13%
Etoposide+Platinum Takano [46] 2008 2/13, 15%
Paclitaxel+Carboplatin Utsunomiya [32] 2006 3/13, 23%
Crotzer [43] 2007 2/7, 29%
Gemcitbine Crotzer [43] 2007 1/9, 11%
Yoshino [47] 2012 1/5, 20%
Docetaxel+Irinotecan Yoshino [47] 2012 1/11, 9%
Temsirolimus Takano [46] 2011 1/5, 20%